18F-FDG PET/CT评估三阴性乳腺癌新辅助化疗疗效的研究进展

三阴性乳腺癌（TNBC）是一种雌激素受体（ER）、孕激素受体（PR）及人表皮生长因子受体2（HER-2）表达均为阴性的乳腺癌亚型，常发生于绝经前的女性，具有预后较差、5年生存率低、侵袭性强、易复发及发生远处转移等特征。目前TNBC主要的治疗方法是手术与化疗，其中新辅助化疗的应用也越来越广泛。近年来，18F-FDG PET/CT在乳腺癌治疗评估中的价值已被广泛研究，PET/CT监测乳腺癌新辅助化疗疗效的价值已得到肯定。该文对18F-FDG PET/CT评估TNBC新辅助化疗疗效的研究进展进行综述。

Advances of assessment with 18F-FDG PET/CT in triple-negative breast cancer during neoadjuvant chemotherapy

Triple-negative breast cancer （TNBC）is a distinctive sub-group of breast cancers that do not express estrogen receptors （ER）, progesterone receptors （PR） and human epidermal growth factor receptor 2 （HER2）. TNBC often happens to premenopausal women, and having special features such as poor prognosis, short 5-year survival, strong tumor invasion, high incidence of local recurrence and distant metastasis. Chemotherapy and surgery are mainly available systemic treatments of TNBC, and neoadjuvant chemotherapy（NAC）has become a widely used systemic treatment. Recently, the value of 18F-FDG PET/CT in breast cancer has been extensively studied, the role of PET/CT monitoring the efficacy of NAC has been a positive result. In this paper, the research progress of assessment with 18F-FDG PET/CT in TNBC during neoadjuvant chemotherapy was reviewed.